Newsroom | 4932 results

NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain...

PHOENIX--(BUSINESS WIRE)--Virginia G. Piper Charitable Trust has appointed Laura Smith as the new director of Eyes On Learning, a coalition of state, local, and national organizations dedicated to improving the vision health of Arizona’s children. About 1-in-4 school-age children have a vision problem that may affect their ability to learn. Healthy vision is especially vital in early childhood and the early grades, when children develop the literacy skills they need to learn to read and be succ...

BEIJING e NANJING, Cina--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) e Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. ("NJCTTQ") hanno annunciato che NTB003 (formerly BCG009), un farmaco candidato iniettabile sviluppato congiuntamente, ha ricevuto l'approvazione come nuovo farmaco sperimentale (IND) dalla National Medical Products Administration (NMPA). L'indicazione per l'approvazione è Orbitopatia tiroidea (TED). Informazioni sull'iniezione...

BEIJING y NANJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Pekín) Co. Ltd. ("Biocytogen", HKEX: 02315) y Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. ("NJCTTQ") anunciaron que NTB003 (ex BCG009), un candidato a fármaco inyectable desarrollado de forma conjunta, ha recibido la aprobación de nuevo fármaco en investigación (IND) de la Administración Nacional de Productos Médicos (NMPA), para tratar la enfermedad ocular tiroidea (EOT). Acerca de la inyección NTB003 NTB003 es un ant...

PÉKIN et NANJING, Chine--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Pékin) Co., Ltd. (« Biocytogen », HKEX : 02315) et Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (« NJCTTQ ») ont annoncé que le NTB003 (anciennement BCG009), un candidat médicament injectable développé conjointement, a reçu l’autorisation Investigational New Drug (IND) de la National Medical Products Administration (NMPA). L’indication approuvée est la maladie oculaire thyroïdienne (TED). À propos du NTB003 Injection Le...

BEIJING & NANJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) en Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. ("NJCTTQ") hebben bekendgemaakt dat voor hun gezamenlijk ontwikkelde injecteerbare kandidaat-geneesmiddel NTB003 (voorheen BCG009), de Investigational New Drug (IND) goedkeuring is verkregen van de National Medical Products Administration (NMPA). De goedgekeurde indicatie is oogziekte van de schildklier (Thyroid Eye Disease -T...

BEIJING und NANJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. („Biocytogen“, HKEX: 02315) und Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. („NJCTTQ“) melden, dass NTB003 (zuvor BCG009), ein gemeinsam entwickelter, injizierbarer Arzneimittelkandidat, die Investigational New Drug (IND)-Zulassung von der National Medical Products Administration (NMPA) für die Indikation endokrine Orbitopathie (Thyroid Eye Disease, TED) erhalten hat. Über NTB003-Injektion NTB003...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 23,400 shares of the company’s common stock to one new employee (th...

BEIJING & NANJING, China--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About NTB003 Injection NTB003 is a second-generation fully huma...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Blink Nourish Lubricating eye drops and Blink Boost Lubricating eye drops. Both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry eyes in a multi-dose bottle. "Blink Nourish and Blink Boost deliver the same science-backed, lo...